Personalis to Participate in the 25th Annual Needham Virtual Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
genomicsmedical
The study of an organism’s complete set of genes and how those genes behave, interact, and influence traits — like reading and interpreting a living organism’s instruction manual. For investors, genomics matters because it drives new drugs, diagnostics and personalized treatments that can create big commercial opportunities or regulatory risks; understanding genomics helps assess a company’s technology edge, market potential and long-term value.
precision oncologymedical
Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.
FREMONT, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the25th Annual Needham Virtual Conference on Wednesday, April 15, 2026.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
